相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide
Giovanni Palladini et al.
ANNALS OF HEMATOLOGY (2012)
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Martha Q. Lacy et al.
BLOOD (2011)
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
Donna E. Reece et al.
BLOOD (2011)
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2010)
Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis
Umit Tapan et al.
BLOOD (2010)
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
Philippe Moreau et al.
BLOOD (2010)
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M. Q. Lacy et al.
LEUKEMIA (2010)
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Donna E. Reece et al.
BLOOD (2009)
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
Ashutosh D. Wechalekar et al.
HAEMATOLOGICA (2008)
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Efstathios Kastritis et al.
HAEMATOLOGICA (2007)
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2007)
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala et al.
BLOOD (2007)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2007)
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Angela Dispenzieri et al.
BLOOD (2007)
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma
Hans P. Sviggum et al.
ARCHIVES OF DERMATOLOGY (2006)
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Giovanni Palladini et al.
BLOOD (2006)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
G Palladini et al.
BLOOD (2005)
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
A Dispenzieri et al.
BLOOD (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
SA Schey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
A Dispenzieri et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2003)
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis
DC Seldin et al.
CLINICAL LYMPHOMA (2003)
分享论文
